News
HSTO
0.500
0.00%
0.000
Weekly Report: what happened at HSTO last week (0408-0412)?
Weekly Report · 3d ago
Weekly Report: what happened at HSTO last week (0401-0405)?
Weekly Report · 04/08 11:49
Weekly Report: what happened at HSTO last week (0325-0329)?
Weekly Report · 04/01 11:46
Weekly Report: what happened at HSTO last week (0318-0322)?
Weekly Report · 03/25 11:50
Weekly Report: what happened at HSTO last week (0311-0315)?
Weekly Report · 03/18 11:48
Weekly Report: what happened at HSTO last week (0304-0308)?
Weekly Report · 03/11 11:44
Weekly Report: what happened at HSTO last week (0226-0301)?
Weekly Report · 03/04 11:47
Weekly Report: what happened at HSTO last week (0219-0223)?
Weekly Report · 02/26 12:03
Weekly Report: what happened at HSTO last week (0212-0216)?
Weekly Report · 02/19 12:06
Weekly Report: what happened at HSTO last week (0205-0209)?
Weekly Report · 02/12 11:52
Weekly Report: what happened at HSTO last week (0129-0202)?
Weekly Report · 02/05 12:04
Weekly Report: what happened at HSTO last week (0122-0126)?
Weekly Report · 01/29 11:49
Weekly Report: what happened at HSTO last week (0115-0119)?
Weekly Report · 01/22 11:54
Weekly Report: what happened at HSTO last week (0108-0112)?
Weekly Report · 01/15 11:49
Weekly Report: what happened at HSTO last week (0101-0105)?
Weekly Report · 01/08 11:54
Weekly Report: what happened at HSTO last week (1225-1229)?
Weekly Report · 01/01 11:47
Weekly Report: what happened at HSTO last week (1218-1222)?
Weekly Report · 12/25/2023 12:02
Weekly Report: what happened at HSTO last week (1211-1215)?
Weekly Report · 12/18/2023 12:10
Weekly Report: what happened at HSTO last week (1204-1208)?
Weekly Report · 12/11/2023 12:03
Weekly Report: what happened at HSTO last week (1127-1201)?
Weekly Report · 12/04/2023 12:02
More
Webull provides a variety of real-time HSTO stock news. You can receive the latest news about Histogen Inc through multiple platforms. This information may help you make smarter investment decisions.
About HSTO
Histogen Inc. is a clinical-stage therapeutics company. The Company is focused on developing clinical and preclinical small molecule pan-caspase and caspase selective inhibitors that protect the body’s natural process to restore immune function. Its product candidates include emricasan, CTS-2090 and CTS-2096. It develops emricasan for acute bacterial skin and skin structure infections (ABSSSI) as well evaluating its use for other infectious diseases. Its pipeline also includes novel preclinical product candidates including CTS-2090 and CTS-2096, which are selective small molecule inhibitors of caspase-1 designed for the treatment of certain inflammatory diseases. Emricasan is an orally available pan-caspase inhibitor designed to reduce the activities of human caspases, which are enzymes that mediate inflammation and apoptosis. CTS-2090 and CTS-2096 are selective caspase-1 inhibitors targeting inflammasome activation and to treat a variety of inflammation mediated diseases.